Rucaparib monocamsylate (Standard)
Rucaparib monocamsylate (Standard) is the analytical standard of Rucaparib monocamsylate (HY-102003). This product is intended for research and analytical applications. Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1859053-21-6
- Formule: C29H34FN3O5S
- Masse moléculaire:555.66
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-10617A
RucaparibPARP Inhibitor -
HY-16106
TalazoparibPARP Inhibitor -
HY-102003
Rucaparib monocamsylatePARP Inhibitor -
HY-13688A
PJ34PARP Inhibitor -
HY-13536
AZD-2461PARP Inhibitor -
HY-132167
SaruparibPARP Inhibitor -
HY-12418
StenoparibPARP Inhibitor -
HY-10619B
Niraparib tosylatePARP Inhibitor -
HY-10617
Rucaparib phosphatePARP Inhibitor -
HY-12022
3-AminobenzamidePARP Inhibitor -
HY-12032
AG14361PARP Inhibitor -
HY-10619
NiraparibPARP Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1859053-21-6
-
Masse moléculaire 555.66
-
Formule C29H34FN3O5S
-
SMILES
FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1.O=S(C[C@@]5(C6(C)C)C(C[C@@]6([H])CC5)=O)(O)=O
-
Synonyms
AG014699 monocamsylate (Standard); PF-01367338 monocamsylate (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6(3), 945-956. [Content Brief]
[2]. J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110(8):1977-84. [Content Brief]
[3]. Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14(2):237-246. [Content Brief]
[4]. Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13(595):eabe8226. [Content Brief]
[5]. Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31(2), 251-264. [Content Brief]
[6]. Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15(4), 1241-1249. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rucaparib monocamsylate (Standard) Related Classifications
HY-102003R Related Classifications
Powered by Bioz